A multiple-domain framework of clinical, economic, and patient-reported outcomes for evaluating benefits of intervention in atopic dermatitis.

Journal of drugs in dermatology : JDD

Volumn 6, Issue 4, 2007, Pages 416-423

  Boguniewicz, Mark ^a   Abramovits, William ^a   Paller, Amy ^a   Whitaker Worth, Diane L ^a   Prendergast, Mary ^a   Cheng, J Wang ^a   Wang, Patrick ^a   Tong, Kuo B ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; NON PRESCRIPTION DRUG; TACROLIMUS;

ADOLESCENT; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL TRIAL; COST OF ILLNESS; ECONOMICS; FEMALE; HOSPITALIZATION; HUMAN; MALE; MULTICENTER STUDY; OINTMENT; PATHOLOGY; PATIENT; PATIENT COMPLIANCE; PRESCHOOL CHILD; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; STATISTICS; TIME; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; DERMATITIS, ATOPIC; DRUGS, NON-PRESCRIPTION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; OINTMENTS; PATIENT COMPLIANCE; PATIENT DROPOUTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34548184918     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)